Professor Michael Brown

Adjunct Professor Centre for Cancer Biology

email Michael.Brown@unisa.edu.au

Research Degree Supervisor

Research

Research focus

Pharmacology and Pharmaceutical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Public Health and Health Services
Biomedical Engineering

Research

Outputs

Research since 2008 is shown below.

Open access indicates that an output is open access.

Journal Articles

Year	Output
2021	MacGregor, M, Safizadeh Shirazi, H, Chan, KM, Ostrikov, K, McNicholas, K, Jay, A, Chong, M, Staudacher, AH, Michl, TD, Zhalgasbaikyzy, A, Brown, MP, Kashani, MN, Di Fiore, A, Grochowski, A, Robb, S, Belcher, S, Li, J, Gleadle, JM & Vasilev, K 2021, 'Cancer cell detection device for the diagnosis of bladder cancer from urine', Biosensors and Bioelectronics, vol. 171, article no. 112699, pp. 1-12. 3
2021	Reid, P, Staudacher, AH, Marcu, LG, Olver, I, Moghaddasi, L, Brown, MP & Bezak, E 2021, 'Characteristic differences in radiation-induced DNA damage response in human papillomavirus-negative and human papillomavirus-positive head and neck cancers with accumulation of fractional radiation dose', Head and Neck, vol. 43, no. 10, pp. 3086-3096. 1
2021	Truong, NT, Gargett, T, Brown, MP & Ebert, LM 2021, 'Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of car-t cell therapies', Cancers, vol. 13, no. 9, article no. 2225, pp. 1-19. Open access 2
2021	Yeo, EC, Brown, MP, Gargett, T & Ebert, LM 2021, 'The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy', Cells, vol. 10, no. 3, pp. 1-25. Open access 7
2020	Burdett, N, Hsu, K, Xiong, L, Tapia-Rico, G, Beckmann, K, Karapetis, C & Brown, MP 2020, 'Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy', Asia Pacific Journal of Clinical Oncology, vol. 16, no. 2, pp. e139-e145. 4 4 2
2020	Ebert, LM, Yu, W, Gargett, T, Toubia, J, Kollis, PM, Tea, MN, Ebert, BW, Bonder, CS, Oksdath Mansilla, M, Scheer, KG, Perrin, SL, Pitson, SM, Gomez, GA & Brown, MP and 8 other authors 2020, 'Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy', Clinical and Translational Immunology, vol. 9, no. 10, article no. e1191, pp. 1-24. Open access 10 9 4
2020	Mislang, A, Mollard, R, Tapia Rico, G, Fairlie, WD, Lee, EF, Harris, TJ, Aston, R & Brown, M 2020, 'A preliminary assessment of oral monepantel's tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors', Cancer Chemotherapy and Pharmacology, vol. 86, no. 5, pp. 589-594. 1
2020	Reid, P, Staudacher, AH, Marcu, LG, Olver, I, Moghaddasi, L & Brown, MP 2020, 'Influence of the human papillomavirus on the radio-responsiveness of cancer stem cells in head and neck cancers', Scientific Reports, vol. 10, no. 1, article no. 2716, pp. 1-8. Open access 3 4 11
2020	Reid, P, Staudacher, AH, Marcu, LG, Olver, I, Moghaddasi, L, Brown, MP, Li, Y & Bezak, E 2020, 'Intrinsic radiosensitivity is not the determining factor in treatment response differences between HPV negative and HPV positive head and neck cancers', Cells, vol. 9, no. 8, pp. 1-14. Open access 1 1 6
2020	Staudacher, AH, Liapis, V, Tieu, W, Wittwer, NL & Brown, MP 2020, 'Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody', Journal of Controlled Release, vol. 327, pp. 779-787. 4 4 2
2019	Brown, MP, Ebert, LM & Gargett, T 2019, 'Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma', Clinical and Translational Immunology, vol. 8, no. 5, article no. e1050, pp. 1-20. Open access 16 17 5
2019	Gargett, T, Truong, N, Ebert, LM, Yu, W & Brown, MP 2019, 'Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype', Cytotherapy, vol. 21, no. 5, pp. 593-602. 9 11 2
2019	Gomez, GA, Oksdath, M, Brown, MP & Ebert, LM 2019, 'New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology', Translational Cancer Research, vol. 8, pp. S606-S611. Open access 4 4
2019	Larkin, J, Brown, MP, Arance, AM, Hauschild, A & Blank, C and 20 other authors 2019, 'An open-label, multicentre safety study of vemurafenib in patients with BRAFⱽ⁶⁰⁰-mutant metastatic melanoma: final analysis and a validated prognostic scoring system', European Journal of Cancer, vol. 107, pp. 175-185. 5 5 3
2019	Mencel, J, Gargett, T, Karanth, N, Pokorny, A, Brown, MP & Charakidis, M 2019, 'Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma', Asia Pacific Journal of Clinical Oncology, vol. 15, no. 6, pp. 383-386. 3 2
2019	Perrin, SL, Samuel, MS, Koszyca, B, Brown, MP, Ebert, LM, Oksdath, M & Gomez, GA 2019, 'Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments', Biochemical Society Transactions, vol. 47, no. 2, pp. 625-638. 45 45 9
2019	Staudacher, AH, Li, Y, Liapis, V, Hou, JJC, Chin, D, Dolezal, O, Adams, TE, van Berkel, PH & Brown, MP 2019, 'APOMAB antibody-drug conjugates targeting dead tumor cells are effective in vivo', Molecular Cancer Therapeutics, vol. 18, no. 2, pp. 335-345. Open access 9 10 1
2019	Zhang, P, Raju, J, Ullah, MA, Au, R, Gargett, T, Brown, MP & Tey, SK 22 total authors 2019, 'Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells', Clinical Cancer Research, vol. 25, no. 6, pp. 1749-1755. Open access 6 7 20
2018	Brown, MP & Mislang, A 2018, 'Cancer immunotherapy: at a new immune frontier', Cancer Forum, vol. 42, no. 1, pp. 3-16. Open access
2018	Dredge, K, Brennan, T V, Hammond, E, Lickliter, JD, Lin, L, Bampton, D, Handley, P, Lankesheer, F, Morrish, G, Yang, Y, Brown, MP & Millward, M 2018, 'A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours', British Journal of Cancer, vol. 118, pp. 1035-1041. Open access 41 38 9
2018	Ebert, LM, Yu, W, Gargett, T & Brown, MP 2018, 'Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology', Biochemical Society Transactions, vol. 46, no. 2, pp. 391-401. 12 12 5
2018	Gargett, T, Abbas, MN, Rolan, P, Price, JD, Gosling, KM, Ferrante, A, Ruszkiewicz, A, Atmosukarto, II, Altin, J, Parish, CR & Brown, MP 2018, 'Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma', Cancer Immunology Immunotherapy, vol. 67, no. 9, pp. 1461-1472. Open access 24 26 3
2018	Long, G V, Atkinson, V, Lo, S, Sandhu, S, Guminski, AD, Brown, MP, Wilmott, JS, Edwards, J, Gonzalez, M, Scolyer, RA, Menzies, AM & McArthur, GA 2018, 'Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study', Lancet Oncology, vol. 19, no. 5, pp. 672-681. 387 385 79
2018	Reid, P, Wilson, P, Li, Y, Marcu, LG, Staudacher, AH, Brown, MP & Bezak, E 2018, 'Experimental investigation of radiobiology in head and neck cancer cell lines as a function of HPV status, by MTT assay', Scientific Reports, vol. 8, article no. 7744, pp. 1-7. Open access 7 7 10
2017	Blank, CU, Larkin, J, Arance, AM, Hauschild, A & Brown, MP and 16 other authors 2017, 'Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis', European Journal of Cancer, vol. 79, pp. 176-184. 23 18
2017	Reid, P, Wilson, P, Li, Y, Marcu, LG, Staudacher, AH, Brown, MP & Bezak, E 2017, 'In vitro investigation of head and neck cancer stem cell proportions and their changes following x-ray irradiation as a function of HPV status', PLoS One, vol. 12, no. 10, article no. e0186186, pp. 1-16. Open access 12 12 3
2017	Staudacher, AH & Brown, MP 2017, 'Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?', British Journal of Cancer, vol. 117, no. 12, pp. 1736-1742. Open access 99 94 11
2017	Tadesse, S, Zhu, G, Mekonnen, LB, Lenjisa, JL, Yu, M, Brown, MP & Wang, S 2017, 'A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors', Future Medicinal Chemistry, vol. 9, no. 13, pp. 1495-1506. Open access 8 8 2
2017	Takhar, H, Singhal, N, Mislang, A, Kumar, R, Kim, L, Selva-Nayagam, S, Pittman, K, Karapetis, C, Borg, M, Olver, IN & Brown, MP 2017, 'Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer', Asia Pacific Journal of Clinical Oncology, vol. 14, no. 1, pp. 91-100. 6 6
2017	Tan, LY, Martini, C, Fridlender, ZG, Bonder, CS, Brown, MP & Ebert, LM 2017, 'Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?', Clinical and Translational Immunology, vol. 6, article no. e135, pp. 1-9. Open access 19 21 3
2016	Al, DR, Staudacher, A, Li, Y, Brown, M & Bezak, E 2016, 'Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy', Medical Physics, vol. 43, no. 11, pp. 6145-6153. 8 7 1
2016	Gargett, T, Yu, W, Dotti, G, Yvon, ES, Christo, SN, Hayball, JD, Lewis, ID, Brenner, MK & Brown, MP 2016, 'GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade', Molecular Therapy, vol. 24, no. 6, pp. 1135-1149. Open access 154 157 8
2016	Takhar, H, Mislang, AR, Singhal, N & Brown, MP 2016, 'Feasibility and kinetics of CD3 + hematopoietic progenitor cell mobilization in response to a single administration of docetaxel chemotherapy and pegfilgrastim in a contemporary cohort of patients with metastatic breast cancer', Asia Pacific Journal of Clinical Oncology, online, pp. 1-8. 1
2016	Tan, LY, Mintoff, C, Johan, MZ, Ebert, BW, Brown, MP, Bonder, CS & Ebert, LM and 8 other authors 2016, 'Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome', Oncotarget, vol. 7, no. 29, pp. 46492-46508. Open access 26 27 2
2015	Christo, SN, Diener, KR, Nordon, RE, Brown, MP, Griesser, HJ, Vasilev, K, Christo, FC & Hayball, JD 2015, 'Scrutinizing calcium flux oscillations in T lymphocytes to deduce the strength of stimulus', Scientific Reports, vol. 5, article no. 7760, pp. 1-8. Open access 13 13 5
2015	Dienstmann, R, Lassen, U, Cebon, J, Desai, J, Brown, MP, Evers, S, Su, F, Zhang, W, Boisserie, F, Lestini, B, Schostack, K, Meresse, V & Tabernero, J 2015, 'First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors', Targeted Oncology, vol. 11, no. 2, pp 149-156. 1 1
2015	Gargett, T & Brown, MP 2015, 'Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2', Cytotherapy, vol. 17, no. 4, pp. 487-495. 64 61 18
2015	Gargett, T, Fraser, CK, Dotti, G, Yvon, ES & Brown, MP 2015, 'BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro', Journal of Immunotherapy, vol. 38, no. 1, pp. 12-23. 23 24 1
2015	Singhal, N, Vatandoust, S & Brown, MP 2015, 'Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity', Cancer Chemotherapy and Pharmacology, vol. 75, no. 2, pp. 325-331. 11 10
2015	Takhar, HS, Singhal, N, Gowda, R, Penniment, M, Takhar, P & Brown, MP 2015, 'Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer', Anti-Cancer Drugs, vol. 26, no. 10, pp. 1069-1077. 14 13 1
2014	Gargett, T & Brown, M 2014, 'The inducible caspase-9 suicide gene system as a 'safety switch' to limit on-target, off-tumor toxicities of chimeric antigen receptor T-cells', Frontiers in Pharmacology, vol. 5, article no. 235, pp. 1-7. Open access 176 168 24
2014	Roder, D, Fong, K, Brown, M, Zalcberg, J & Wainwright, C 2014, 'Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia', European Journal of Cancer Care, vol. 23, no. 6, pp. 721-727. 16 13 1
2014	Shahnam, A, Roder, DM, Tracey, EA, Neuhaus, SJ, Brown, MP & Sorich, MJ 2014, 'Can cancer registries show whether treatment is contributing to survival increases for melanoma of the skin at a population level?', Journal of Evaluation in Clinical Practice, vol. 20, no. 1, pp. 74-80. Open access 2 2 6
2014	Staudacher, AH, Al-Ejeh, F, Fraser, CK, Darby, JM, Roder, DM, Ruszkiewicz, A, Manavis, J & Brown, MP 2014, 'The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®', EJNMMI Research, vol. 4, article no. 2, pp. 1-13. Open access 19 17
2013	Al-Ejeh, F, Shi, W, Miranda, M, Simpson, PT, Vargas, AC, Song, S, Wiegmans, AP, Swarbrick, A, Welm, AL, Brown, MP, Chenevix-Trench, G, Lakhani, SR & Khanna, KK 2013, 'Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor', Journal of Nuclear Medicine, vol. 54, no. 6, pp. 913-921. Open access 54 49 15
2013	Brown, MP & Burdett, N 2013, 'Targeted therapies, aspects of pharmaceutical and oncological management', Cancer Forum, vol. 37, no. 1, pp. 70-80. Open access 4
2013	Nathanson, KL, Martin, A-M, Wubbenhorst, B, Greshock, J, Letrero, R, D'Andrea, K, O'Day, S, Infante, JR, Falchook, GS, Arkenau, H-T, Millward, M, Brown, MP, Pavlick, A, Davies, MA, Ma, B, Gagnon, R, Curtis, M, Lebowitz, PF, Kefford, R & Long, G V 2013, 'Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)', Clinical Cancer Research, vol. 19, no. 17, pp. 4868-4878. Open access 124 121 5
2013	Pishas, K I, Neuhaus, SJ, Clayer, MT, Adwal, A, Brown, MP, Evdokiou, A, Callen, DF & Neilsen, PM 2013, 'Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy', Oncology Reports: An International Journal Devoted to Fundamental and Applied Research in Oncology, vol. 30, no. 1, pp. 471-477. Open access 2 3
2013	Pishas, K I, Neuhaus, SJ, Clayer, MT, Schreiber, AW, Lawrence, DM, Perugini, M, Whitfield, RJ, Farshid, G, Manavis, J, Chyrssidis, S, Mayo, BJ, Haycox, RC, Ho, K, Brown, MP, D'Andrea, RJ, Evdokiou, A, Thomas, DM, Desai, J, Callen, DF & Neilsen, PM 2013, 'Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling', Cancer Research, vol. 74, no. 3, pp. 1-11. Open access 17 17 1
2013	Stevens, NE, Fraser, C, Alsharifi, M, Brown, MP, Diener, KR & Hayball, JD 2013, 'An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant', PLoS One, vol. 8, no. 7, article no. e68895, pp. 1-10. Open access 6 6
2012	Barrios, CH, Herandez-Barajas, D, Brown, MP, Lee, S-H, Fein, L, Liu, J-H, Hariharan, S, Martell, BA, Yuan, J, Bello, A, Wang, Z, Mundayat, R & Rha, S-Y 2012, 'Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma', Cancer, vol. 118, no. 5, pp. 1252-1259. Open access 77 75
2012	Brown, MP 2012, 'Is the induction of tumor cell senescence the key to a good irradiated tumor vaccine?', Molecular Therapy, vol. 20, no. 5, pp. 884-886. Open access
2012	Christo, SN, Sarvestani, GT, Griesser, SS, Coad, BR, Griesser, HJ, Vasilev, K, Brown, MP, Diener, KR & Hayball, JD 2012, 'Individual and population quantitative analyses of calcium flux in T-Cells activated on functionalized material surfaces', Australian Journal of Chemistry: An International Journal for Chemical Science, vol. 65, no. 1, pp. 45-49. 7 7 3
2012	Falchook, GS, Long, G V, Kurzrock, R, Kim, KB, Arkenau, TH, Brown, MP, Hamid, O, Infante, JR, Millward, M, Pavlick, AC, O'Day, SJ, Blackman, SC, Curtis, CM, Lebowitz, P, Ma, B, Ouellet, D & Kefford, RF 2012, 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial', The Lancet, vol. 379, no. 9829, pp. 1893-1901. Open access 708 656 29
2012	Miller, DS, Brown, MP, Howley, PM & Hayball, JD 2012, 'Current and emerging immunotherapeutic approaches to treat and prevent peanut allergy', Expert Review of Vaccines, vol. 11, no. 12, pp. 1471-1481. 5 5 9
2011	Al-Ejeh, F, Smart, CE, Morrison, BJ, Chenevix-Trench, G, López, JA, Lakhani, SR, Brown, MP & Khanna, KK 2011, 'Breast cancer stem cells: treatment resistance and therapeutic opportunities', Carcinogenesis, vol. 32, no. 5, pp. 650-658. Open access 102 92 3
2011	Bishnoi, S, Pittman, K, Yeend, S, Brown, M, Koczwara, B, Kotasek, D, Patterson, W, Townsend, A, Luke, C & Price, T 2011, 'Gemcitabine and carboplatin in carcinoma of unknown primary site (CUP) in elderly patients: analysis of a phase 2 Adelaide Cancer Trials and Education Collaborative (ACTEC) study', Journal of Geriatric Oncology, vol. 2, no. 4, pp. 233-238. 1 1 1
2011	Brown, MP 2011, 'Do human lymphocyte antigens play a role in the clinical antimelanoma activity of ipilimumab?', Immunotherapy, vol. 3, no. 5, pp. 595-599. 2 2
2011	Kirkwood, JM, Gonzalex, R, Reintgen, D, Clingan, PR, McWilliams, RR, de Alwis, DP, Zimmermann, A, Brown, MP, Ilaria, RL & Millward, MJ 2011, 'A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma', Cancer, vol. 117, no. 20, pp. 4732-4739. Open access 18 17
2011	Kurkuri, MD, Al-Ejeh, F, Shi, JY, Palms, D, Prestidge, C, Griesser, HJ, Brown, MP & Thierry, B 2011, 'Plasma functionalized PDMS microfluidic chips : towards point-of-care capture of circulating tumor cells', Journal of Materials Chemistry, vol. 21, no. 24, pp. 8841-8848. 31 29 9
2011	Lousberg, EL, Diener, KR, Brown, MP & Hayball, JD 2011, 'Innate immune recognition of poxviral vaccine vectors', Expert Review of Vaccines, vol. 10, no. 10, pp. 1435-1449. 12 14 3
2011	Lousberg, EL, Diener, KR, Fraser, CK, Phipps, S, Foster, PS, Chen, W, Uematsu, S, Akira, S, Robertson, SA, Brown, MP & Hayball, JD 2011, 'Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition', Journal of Virology, vol. 85, no. 7, pp. 3385-3396. Open access 9 9
2011	Pishas, K I, Al-Ejeh, F, Zinonos, I, Kumar, R, Evdokiou, A, Brown, MP, Callen, DF & Neilsen, PM 2011, 'Nutlin-3a is a potential therapeutic for Ewing sarcoma', Clinical Cancer Research, vol. 17, no. 3, pp. 494-504. Open access 55 56 3
2010	Al-Ejeh, F, Kumar, R, Wiegmans, A, Lakhani, S, Brown, M & Khanna, K 2010, 'Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes', Oncogene, vol. 29 no. 46, pp. 6085-6098. Open access 100 96
2010	Fraser, C, Diener, KR, Lousberg, E, Both, Gw, Ward, L, Brown, MP & Hayball, JD 2010, 'Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus', Clinical and Vaccine Immunology, vol. 17, no. 11, pp. 1679-1686. Open access 5 5
2010	Fraser, CK, Brown, MP, Diener, KR & Hayball, JD 2010, 'Unravelling the complexity of cancer-immune system interplay', Expert Review of Anticancer Therapy: An Essential Contribution to Decision Making in Cancer Care, vol. 10, no. 6, pp. 917-934. 4 4
2010	Fraser, CK, Lousberg, EL, Guerin, LR, Hughes, TP, Brown, MP, Diener, KR & Hayball, JD 2010, 'Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo', Cancer Biology and Therapy, vol. 10, no. 7, pp. 715-727. Open access 10 10
2009	Al-Ejeh, F, Darby, JM & Brown, MP 2009, 'Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors', PLoS One, vol. 4 no. 2, article no. e4630, pp. 1-13. Open access 25 22
2009	Al-Ejeh, F, Darby, JM, Thierry, B & Brown, MP 2009, 'A simplified suite of methods to evaluate chelator conjugation of antibodies : effects on hydrodynamic radius and biodistribution', Nuclear Medicine and Biology, vol. 36, no. 4, pp. 395-402. 27 25
2009	Diener, K, Woods, AE, Manavis, J, Brown, MP & Hayball, JD 2009, 'Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression', Laboratory Investigation, vol. 89, no. 2, pp. 142-151. Open access 14 14
2009	Fraser, C, Blake, SJ, Diener, KR, Lyons, A, Brown, MP, Hughes, T & Hayball, JD 2009, 'Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo', Experimental Hematology, vol. 37, no. 2, pp. 256-265. 52 50
2009	Moldenhauer, LM, Diener, K, Thring, DM, Brown, MP, Hayball, JD & Robertson, SA 2009, 'Cross-presentation of male seminal fluid antigens elicits T cell activation to initiate the female immune response to pregnancy', Journal of Immunology, vol. 182, no. 12, pp. 8080-8093. Open access 119 153
2009	Thierry, B, Al-Ejeh, F, Brown, MP, Majewski, PJ & Griesser, HJ 2009, 'Immunotargeting of functional nanoparticles for MRI detection of apoptotic tumor cells', Advanced Materials, vol. 21, pp. 541-545. 29 25
2009	Thierry, B, Al-Ejeh, F, Khatri, A, Yuan, Z, Russell, PJ, Ping, S, Brown, MP & Majewski, P 2009, 'Multifunctional core-shell magnetic cisplatin nanocarriers', Chemical Communications, vol. 2009, no. 47, pp. 7348-7350. 26 28
2008	Diener, K, Lousberg, EL, Beukema, EL, Yu, A, Howley, PM, Brown, MP & Hayball, JD 2008, 'Recombinant fowlpox virus elicits transient cytotoxic T cell responses due to suboptimal innate recognition and recruitment of T cell help', Vaccine, vol. 26, no. 29-30, pp. 3566-3573. 9 7
2008	Luke, C, Koczwara, B, Karapetis, CS, Pittman, K, Price, TJ, Kotasek, D, Beckmann, KR, Brown, MP & Roder, DM 2008, 'Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: Implications for research and clinical care', Australian and New Zealand Journal of Public Health, vol. 32, no. 4, pp. 383-389. 25 25

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Adelaide Cancer Centre	AUSTRALIA
Adelaide Radiotherapy Centre	AUSTRALIA
Angeles Clinic and Research Institute	UNITED STATES
Austin Hospital	AUSTRALIA
Australian National University	AUSTRALIA
Bayer	UNITED STATES
Baylor College of Medicine	UNITED STATES
Bristol-Myers Squibb, US	AUSTRALIA
Centro Oncologico de Rosario	ARGENTINA
Clinical Network Services	AUSTRALIA
Copenhagen University Hospital	DENMARK
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation)	AUSTRALIA
Department of Health	AUSTRALIA
Duke University	UNITED STATES
Eli Lilly	AUSTRALIA
Flinders Medical Centre	AUSTRALIA
Flinders University	AUSTRALIA
Garvan Institute of Medical Research	AUSTRALIA
GenesisCare	AUSTRALIA
GlaxoSmithKline	AUSTRALIA
Griffith University	AUSTRALIA
Hanson Institute	AUSTRALIA
Hebrew University	MEXICO
Hospital Clinic Barcelona	SPAIN
Hospital Universitario	UNITED STATES
Houston Methodist Hospital	UNITED STATES
Institute of Medical and Veterinary Science	AUSTRALIA
Lipotek Pty Ltd	AUSTRALIA
Ludwig Institute for Cancer Research	AUSTRALIA
Mayo Clinic	UNITED STATES
Monash University	AUSTRALIA
Motherson Innovations Australia	AUSTRALIA
Netherlands Cancer Institute	NETHERLANDS
New York Medical College	UNITED STATES
New York University	UNITED STATES
Novartis Pharmaceuticals Corporation	UNITED STATES
Nucleus Network	AUSTRALIA
Olivia Newton John Cancer Research Institute	AUSTRALIA
Osaka Prefecture University	JAPAN
Peter MacCallum Cancer Centre	AUSTRALIA
Pfizer Oncology	UNITED STATES
PharmAust	AUSTRALIA
Pontifical Catholic University of Rio Grande do Sul (PUCRS)	BRAZIL
Prince of Wales Hospital	AUSTRALIA
Private Individual	AUSTRALIA
QIMR Berghofer Medical Research Institute	AUSTRALIA
Queen Elizabeth Hospital	AUSTRALIA
Queensland Institute of Medical Research	AUSTRALIA
Roche Diagnostics	SWITZERLAND
Royal Adelaide Hospital	AUSTRALIA
Royal Darwin Hospital	AUSTRALIA
Royal Melbourne Hospital	AUSTRALIA
SA Pathology	AUSTRALIA
Sarah Cannon Research Institute	UNITED STATES
Sarcoma Research Group	AUSTRALIA
Seoul National University	KOREA, REPUBLIC OF (SOUTH)
Sir Charles Gardiner Hospital	AUSTRALIA
Southern Medical Day Care Centre	AUSTRALIA
Taipei Veterans General Hospital	TAIWAN
TBG Diagnostics	AUSTRALIA
The Royal Marsden NHS Foundation Trust	UNITED KINGDOM
University Clinic Schleswig-Holsteinl	GERMANY
University of Adelaide	AUSTRALIA
University of British Columbia	CANADA
University of Colorado	UNITED STATES
University of New South Wales	AUSTRALIA
University of Newcastle	AUSTRALIA
University of North Carolina at Chapel Hill	UNITED STATES
University of Pennsylvania	UNITED STATES
University of Pittsburgh	UNITED STATES
University of Queensland	AUSTRALIA
University of South Australia	AUSTRALIA
University of South Florida	UNITED STATES
University of Sydney	AUSTRALIA
University of Texas	UNITED STATES
University of Utah	UNITED STATES
University of Western Australia	AUSTRALIA
UniversityHospital Schleswig-Holstein	GERMANY
Vall d'Hebron University Hospital	SPAIN
Virax Holdings Limited	AUSTRALIA
Yonsei University College of Medicine	KOREA, REPUBLIC OF (SOUTH)
Zucero Therapeutics	AUSTRALIA

Teaching & student supervision

Research degree supervision

Supervisions from 2010 shown

Thesis title	Student status
Finding out how well chimeric antigen receptor (CAR)-T cells kill brain tumour cells	Current
Development and evaluation of ovine polyclonal antibody therapies for the treatment of severe influenza infection and bacterial sepsis	Completed
Dissecting the mechanisms involved in the induction of immunity to recombinant fowlpox virus	Completed
Evaluation of the immunomodulatory properties of dasatinib for improved application in combinatorial immunotherapy regimens	Completed
Optimising CAR T cell manufacturing for solid cancers	Completed
The use of biomaterials to investigate and modulate innate and adaptive immunity	Completed
Vasculogenic mimicry: regulation and function in melanoma	Completed

more less

Professor Michael Brown

About me

About me

Centre for Cancer Biology

About me

Professional Associations

Experience

Qualifications

Research

Research focus

Projects

Outputs

Journal Articles

External engagement & recognition

Collaborations

Collaborations

Teaching & student supervision

Courses and programs

Research degree supervision

Gallery